If we designed airplanes like we design drugs

Area of Science:

• Aerospace Engineering
• Pharmaceutical Sciences
• Computational Chemistry

Background:

• Early aircraft development relied on repurposed components and empirical testing, often leading to failures.
• Traditional drug discovery mirrors this early approach, synthesizing and testing molecules with high failure rates.
• The aerospace industry has significantly advanced through computer-aided design (CAD) and simulation.

Purpose of the Study:

• To compare the evolution of computer-based design in aerospace with progress in computer-aided drug design (CADD).
• To highlight the benefits of simulation and modeling in accelerating design and reducing failure rates.
• To identify the reasons for the slower adoption of advanced computational tools in pharmaceutical research.

Main Methods:

• Historical analysis of design methodologies in aerospace.
• Comparative review of computational approaches in aerospace and drug design.
• Assessment of software development and funding trends in pharmaceutical research.

Main Results:

• Aerospace extensively utilizes iterative computer-based design and simulation, drastically reducing physical prototypes.
• Drug discovery remains largely empirical, with CADD tools underdeveloped and underutilized compared to aerospace.
• Pharmaceutical software development is primarily entrepreneurial, lacking robust government and industry support for simulation tools.

Conclusions:

• The pharmaceutical industry lags approximately 30 years behind aerospace in adopting simulation and modeling for design.
• Increased investment in computational tools and recognizing the value of simulation are crucial for pharmaceutical innovation.
• Bridging the gap in computational design capabilities could significantly improve drug discovery efficiency and success rates.